Use of 1,6-fructo strontium biphosphate for pharmaceuticals

A technology of fructose diphosphate and strontium salt, applied in the direction of drug combinations, diseases, carbohydrate active ingredients, etc., can solve problems such as testicular degeneration that cannot be corrected, and achieve low male sexual function and other diseases, with obvious curative effect, The effect of both specimens

Active Publication Date: 2009-02-04
NANJING TECH UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] At present, there is a lack of drugs that can prevent testicular degeneration and maintain normal testicular function and morphology. The most commonly used drug is testosterone, but testosterone supplementation cannot correct testicular degeneration

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of 1,6-fructo strontium biphosphate for pharmaceuticals
  • Use of 1,6-fructo strontium biphosphate for pharmaceuticals
  • Use of 1,6-fructo strontium biphosphate for pharmaceuticals

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Several male KM mice were randomly divided into 6 groups. Except group A (normal group), the other groups were given 100mg.kg s.c per day -1 D-galactose once, for 28 consecutive days, caused the male dysfunction model. Group A s.c was given the same volume of normal saline as normal control; Group B was the pathological model group; Groups C, D, E, and F were given i.g 50mg.kg at the same time -1 , 100mg.kg -1 , 200mg.kg -1 , 400mg.kg -1 The FDP-Sr was administered once a day for 28 consecutive days. Groups A and B were given the same volume of distilled water as the other groups.

[0043] After 28 days, observations were made at night. Take one male mouse from each cage and put it under dark light to adapt to the environment for 5 minutes, then put two female mice into it, and start to record the incubation period and the number of times of catching female mice. The experimental results are shown in Table 1:

[0044] Table 1 Latency period and times of catching ...

Embodiment 2

[0049] After the catch test, the male rats were dissected: the testes, epididymis, seminal vesicles, preputial glands, and levator ani muscles were taken out, weighed accurately, and the organ index (organ / body weight ratio) was calculated.

[0050]The experimental results are shown in Table 2. figure 1 :

[0051] Table 2 Weight index of testes and accessory sex organs in male mice (mean±SD, mg / 10g)

[0052]

[0053] * P** P<0.01vs normal group; #P<0.05, ##P<0.01vs model group.

[0054] From the above results, it can be seen that after FDP-Sr treatment, except for the low-dose FDP-Sr group (50mg / kg), all other groups showed significant improvement. The ratios of gonads / body weight were increased to varying degrees (P<0.05).

Embodiment 3

[0056] Biochemical enzymatic determination: Take the right testis tissue to make homogenate with normal saline, take the supernatant, measure glutamyl transpeptidase (γ-GT), lactate dehydrogenase (LDH), succinate dehydrogenase (SDH ) and acid phosphatase (ACP).

[0057] The experimental results are shown in Table 3. figure 2 ;Table 4, image 3 ;table 5, Figure 4 ; Table 6, Figure 5 .

[0058] Table 3 FDP-Sr treatment improves glutamyl transpeptidase activity in testes. (Mean±SD, U / g protein)

[0059]

[0060] ** P<0.01vs normal group; ##P<0.01vs model group.

[0061] Glutamyl transpeptidase (γ-GT) is an enzyme that promotes sperm maturation, catalyzes glutathione to generate L-glutamic acid, and provides the acidic environment required for sperm maturation. In the model of male hypofunction caused by D-galactose, the level of γ-GT decreased (P-1 , 400mg.kg -1 In the dose group, γ-GT was slightly higher than that in the normal group (P<0.01).

[0062] Table 4 FD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses an application of tristrontium difructose-1.6-diphosphate in preparation of medicine for preventing and curing retrograde affection of testis or male sexual hypofunction. Besides, said invention also can be used for curing male infertility.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to the application of strontium fructose 1,6-diphosphate in pharmacy, in particular to the application of strontium 1,6-fructose diphosphate in the preparation, prevention and treatment of testicular degenerative diseases and male patients caused by testicular degenerative diseases Drug use in sexual hypofunction and infertility. Background technique [0002] The health of the male population is closely related to normal testicular function and morphology. After the age of 50 to 60 years old, due to the gradual degenerative changes of the testicles, the secretion of testosterone decreases, and the syndrome of "andropause" (Andropause) appears. It has been reported in the literature that after the age of 50 in Japanese men, the testicular weight decreased significantly (Mori C, Hamamatsu A, Fukata H, et. al. Anat Sci Int. 2002, 77(2): 109-16.). For this kind of male sexual dysfunction caused ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/70A61P15/08
Inventor 应汉杰欧阳平凯张琪吕浩
Owner NANJING TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap